Do high levels of CA 19-9 in women with mature cystic teratomas of the ovary warrant further evaluation?
To evaluate the serum levels of tumor markers (particularly CA 19-9) in patients with ovarian mature cystic teratomas (MCT) with respect to age, size, bilaterality, menopause, presence of adhesions, complications and the postoperative levels. We evaluated clinical characteristics and tumor markers of 157 patients with MCT of the ovary operated at our clinic. CA19-9 was the only tumor marker with a mean serum level (46.95 +/- 101.11 U/ml) above the cut-off value and the elevated rate was 33.1%. Tumor size, presence of adhesions and CA 125 levels were significantly higher in patients with elevated CA 19-9. Bilaterality rate was 10.8%. The most common complication was torsion (6.4%). We suggest that elevated levels of CA 19-9 may be expected in MCTs of the ovary and that they will probably be decreased postoperatively. Therefore, postponing evaluation of other possible sources of CA 19-9 elevation in asymptomatic and young patients is more common sense.